Clinical Study
Single Ascending Dose Safety and Pharmacokinetics of CDRI-97/78: First-in-Human Study of a Novel Antimalarial Drug
Table 1
Demographic characteristics of the volunteers included in the studies.
| | Characteristic | 80 mg | 160 mg | 320 mg | 400 mg | 500 mg | 600 mg | 700 mg | Placebo | | | | | | | | |
| | Age in years; Mean (SD) | 28.5 (10.93) | 27.5 (4.32) | 25.0 (7.12) | 25.2 (2.13) | 21.3 (3.53) | 25.2 (7.67) | 23.0 (1.41) | 25.4 (5.75) | | Height in cm; Mean (SD) | 170.5 (5.33) | 167.5 (5.8) | 166.7 (6.44) | 167.3 (4.08) | 167.0 (3.57) | 170.2 (5.77) | 171.0 (1.41) | 171.3 (4.89) | | Weight in kg; Mean (SD) | 58.6 (9.72) | 69.0 (13.57) | 56.6 (8.84) | 61.6 (7.17) | 59.6 (6.47) | 61.3 (12.67) | 63.5 (2.12) | 60.7 (8.43) | | BMI (kg/m2); Mean (SD) | 20.1 (3.04) | 24.8 (5.89) | 20.3 (2.14) | 22.0 (2.35) | 21.4 (2.5) | 21.7 (0.36) | 20.7 (2.75) | 21.4 (3.4) |
|
|
